Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CASP6 | P55212 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HCAR3 | P49019 | 10/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12473428 | 0.86 | VCAM1 (0.54) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL9185447 | 0.85 | CASP6 (0.64) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL20572634 | 0.84 | POLB (0.62) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL28909765 | 0.84 | POLB (0.62) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL3530451 | 0.84 | VCAM1 (0.71) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL9183692 | 0.84 | POLB (0.62) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL19182681 | 0.83 | VCAM1 (0.48) | POLBMEN1KMT2ALMNAVCAM1 | |
| SCHEMBL11973460 | 0.82 | VCAM1 (0.77) | POLBLMNAVCAM1 | |
| SCHEMBL9499862 | 0.81 | POLB (0.59) | POLBCASP6MEN1KMT2ATSHR | |
| SCHEMBL135289 | 0.79 | CASP6 (0.47) | POLBCASP6MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS INC (KR) | 2024-08-01 | — | — | US | disclosed |
| CN-118201641-A | Novel degradant-anti-CD 33 antibody conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| EP-4346910-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | Orum Therapeutics Inc. (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (FR) | 2023-10-26 | — | — | US | disclosed |
| CN-115867322-A | Novel degradant conjugates | 奥隆制药 | 2023-03-28 | — | — | CN | disclosed |
| EP-4126067-A1 | NEODEGRADER CONJUGATES | Orum Therapeutics Inc. (KR) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022254377-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2022-12-08 | — | — | WO | disclosed |
| WO-2021198965-A1 | NEODEGRADER CONJUGATES | ORUM THERAPEUTICS, INC. (KR) | 2021-10-07 | — | — | WO | disclosed |
| WO-2012039499-A1 | DEPROTECTION METHOD USING GLUTATHIONE-S-TRANSFERASE AND USE THEREOF | 独立行政法人理化学研究所 (JP) | 2012-03-29 | — | — | WO | disclosed |
| CN-101133026-B | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE | 2011-07-06 | — | — | CN | disclosed |
| CN-101133026-A | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | CN | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
| US-5378704-A | Non-peptidic angiotensin-II-receptor-antagonists | E. R. SQUIBB & SONS, INC. (US) | 1995-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | POLB 3997/4885CASP6 3419/4885MEN1 2956/4885 |
| US-20240252671-A1 | NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES | NEU3, FCGR3B, ENTPD3 | POLB 2448/4885CASP6 3213/4885MEN1 3384/4885 |
| US-20230338564-A1 | NEODEGRADER CONJUGATES | CD44, FOLR1, CD47 | POLB 259/4885CASP6 3479/4885MEN1 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.